Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation

Eculizumab is effective for complement-mediated thrombotic microangiopathy (CM-TMA), also known as atypical hemolytic uremic syndrome. Although lifelong therapy had been suggested, discontinuation does not universally lead to relapse. Comprehensive data evaluating risk factors for recurrence followi...

Descripción completa

Detalles Bibliográficos
Autores principales: Acosta-Medina, Aldo A., Moyer, Ann M., Go, Ronald S., Willrich, Maria Alice V., Fervenza, Fernando C., Leung, Nelson, Bourlon, Christianne, Winters, Jeffrey L., Spears, Grant M., Bryant, Sandra C., Sridharan, Meera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Platelets and Thrombopoiesis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9881046/
https://www.ncbi.nlm.nih.gov/pubmed/35533258
http://dx.doi.org/10.1182/bloodadvances.2021006416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9881046/
https://www.ncbi.nlm.nih.gov/pubmed/35533258
http://dx.doi.org/10.1182/bloodadvances.2021006416

Ejemplares similares